NewsNovo
disclosed a September investor presentation in an 8-K filing, detailing financial position and clinical trial data for its lead candidate INBRX-106.
The company reported holding $219.5 million in cash and cash equivalents as of August 6, 2026.
The presentation outlines a strategic focus on next-generation OX40 agonism to enhance the efficacy of PD-1 inhibitors in various cancer types.
The company highlighted data from the HexAgon study, which compares INBRX-106 in combination with pembrolizumab against pembrolizumab monotherapy in first-line head and neck squamous cell carcinoma (HNSCC).
Keep reading